Oerlikon has completed a major strategic reset. With the Barmag divestment closed, the group is now focused on surface technologies and advanced materials—placing additive manufacturing inside a broader, more integrated industrial platform.
For AM investors, this changes how Oerlikon should be viewed. The attraction is not pure-play printer exposure. It is ownership of powders, coatings, application know-how and service infrastructure around high-value manufacturing processes.
What changed?
- Oerlikon completed the Barmag sale in February 2026.
- 2025 order intake increased 6.5% at constant FX.
- Aviation and energy supported sales while weaker industrial end markets lagged.
- Management expects low-single-digit organic growth in 2026 and an operational EBITDA margin around 17.5%.
- Oerlikon Metco expanded direct access to its MetcoMed medical-grade L-PBF powders.
AM is part of the materials moat
Oerlikon’s strongest AM position is not simply machine ownership. The company controls high-performance powder portfolios, application engineering and a global surface-solutions network. That can matter in medical, aerospace and energy applications where qualification and material consistency create switching costs.
The MetcoMed portfolio illustrates the strategy: certified-quality titanium and cobalt alloys sold into orthopedic and dental production rather than generic commodity powder markets.
Why focus could improve returns
The Barmag divestment removes a large unrelated activity and should make capital allocation easier to judge. If management directs more resources toward advanced materials, aerospace and medical applications, additive manufacturing can benefit without needing to become a standalone growth segment.
What would prove the thesis?
- Aviation and medical materials continue to outgrow weaker industrial markets.
- Advanced-materials mix supports margin expansion.
- AM powder products gain recurring production customers.
- The simplified portfolio improves cash conversion and returns on capital.
What would break the thesis?
- AM remains strategically interesting but financially immaterial.
- Industrial weakness overwhelms aerospace and medical growth.
- Portfolio simplification fails to improve margins or cash flow.
Research conclusion
Oerlikon is becoming a cleaner advanced-materials story. Additive manufacturing fits best as one application layer inside a larger moat built around powders, coatings and qualified industrial processes.
Research use only. This article is not investment advice.
Read the full Oerlikon investor profile →